N/A
Completed N=223
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Breast Cancer · Metastatic Castration Resistant Prostate Cancer · Kidney Cancer · Non-Small Cell Lung Cancer
Source: ClinicalTrials.gov NCT00428220 ↗
Enrolled (actual)
223
Serious AEs
40.4%
Results posted
Nov 2015
Primary outcomePrimary: Number of Participants With Treatment-emergent Adverse Events (AEs) (All Causalities) — 221; 90; 174; 24 participants
Summary
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Treatment-emergent Adverse Events (AEs) (All Causalities) |
221; 90; 174; 24; 67; 66 | — |
| PRIMARY Number of Participants With Treatment-emergent AEs (Treatment-Related) |
217; 39; 146; 0; 29; 64 | — |
Eligibility Criteria
Inclusion Criteria
- Must have ended treatment from one of the following sunitinib studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.
Exclusion Criteria
- See inclusion criteria
Data sourced from ClinicalTrials.gov (NCT00428220). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.